*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*

**Yonghe Medical Group Co., Ltd.**
**雍禾醫療集團有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 2279)**

# NOTICE OF ANNUAL GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that the annual general meeting ("**AGM**") of Yonghe Medical Group Co., Ltd. (the "**Company**") will be held at 2:00 p.m. on May 19, 2026 at Meeting Room, 16/F, KunTai International Building, Office Tower No. 12B Chaowai Street, Chaoyang District Beijing, PRC:

A. To consider and pass (with or without amendments) the following ordinary resolutions of the Company as appropriate:

1. To accept, consider and adopt the audited consolidated financial statements of the Company and the reports of the board of directors (the "**Directors**") of the Company (the "**Board**") and of auditors of the Company for the year ended December 31, 2025;

2. To declare a final dividend of RMB0.076 (excluding treasury shares) (equivalent to HK$0.086) per share for the year ended December 31, 2025;

3. To re-elect Mr. Zhang Yu as an executive director of the Company;

4. To re-elect Ms. Liang Jihong as an independent non-executive director of the Company;

5. To re-elect Mr. Chan Peng Kuan as an independent non-executive director of the Company;

6. To re-elect Mr. Li Xiaopei as an independent non-executive director of the Company;

7. To authorize the Board to fix the remuneration of the directors of the Company;

8. To re-appoint PricewaterhouseCoopers as auditors of the Company and to authorize the Board to fix their remuneration;

9. "**THAT**:

(a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to purchase its shares, subject to and in accordance with the applicable laws, be and is hereby generally and unconditionally approved;

(b) the total number of shares of the Company to be purchased pursuant to the approval in paragraph (a) above shall not exceed 10% of the total issued shares (excluding treasury shares) of the Company as at the date of passing of this resolution (subject to adjustment in case of subdivision and consolidation of Shares) and the said approval shall be limited accordingly; and

(c) for the purposes of this resolution, "Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the revocation or variation of the authority given under this resolution by an ordinary resolution passed by the Shareholders in general meeting; and

(iii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held.";

10. "**THAT**:

(a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to allot, issue and deal with unissued shares (including any sale or transfer of treasury shares) of the Company and to make or grant offers, agreements and options which might require the exercise of such powers be and is hereby generally and unconditionally authorized;

(b) the approval in paragraph (a) above shall authorize the Directors to make or grant offers, agreements and options during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;

(c) the total number of shares allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of options under the share option scheme of the Company; and

(iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company,

shall not exceed 20% of the total issued shares (excluding treasury shares) of the Company as at the date of passing of this resolution (subject to adjustment in case of subdivision and consolidation of Shares) and the said approval shall be limited accordingly; and

(d) for the purposes of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the revocation or variation of the authority given under this resolution by an ordinary resolution passed by the Shareholders in general meeting; and

(iii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held.

"Rights Issue" means an offer of shares open for a period fixed by the Directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange).";

11. "**THAT**:

conditional upon the passing of the resolutions set out in items 9 and 10 of the notice convening this meeting (the "**Notice**"), the general mandate referred to in the resolution set out in item 10 of the Notice be and is hereby extended by the addition to the total number of shares which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to such general mandate of an amount

representing the total number of shares purchased by the Company pursuant to the mandate referred to in the resolution set out in item 9 of the Notice, provided that such amount shall not exceed 10% of the total issued shares (excluding treasury shares) of the Company as at the date of passing of this resolution."

B. To consider and, if thought fit, pass with or without modification the following resolution as a special resolution:

**SPECIAL RESOLUTION**

12. "**THAT** the amendments to the memorandum and articles of association of the Company (the "**Memorandum and Articles of Association**") set out in Appendix III to the circular of the Company dated April 16, 2026 of which this notice forms part be and are hereby approved and the fourth amended and restated Memorandum and Articles of Association (a copy of which having been produced before the meeting and signed by the chairman of the meeting for the purpose of identification) be and is hereby adopted as the new Memorandum and Articles of Association."

By Order of the Board
**Yonghe Medical Group Co., Ltd.**
**Zhang Yu**
*Chairman*

April 16, 2026

*Notes:*

1. Any shareholder of the Company entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not to be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.

2. Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the general meeting(s) of the Company. For the avoidance of doubt, solely from the perspectives of the Listing Rules, the Company shall, upon depositing any treasury shares in the CCASS, abstain from voting at any of its general meeting(s) in relation to those shares.

3. To be effective, a form of proxy together with the power of attorney or other authority (if any), under which it is signed or a notarially certified copy of that power or authority, must be deposited at the Hong Kong branch share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours (not later than 2:00 p.m. on May 17, 2026) before the time appointed for the holding of the AGM or any adjournment thereof. Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the AGM and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

4. To ascertain shareholders' eligibility to attend and vote at the AGM, the register of members of the Company will be closed from May 14, 2026 to May 19, 2026, both days inclusive, during which period no transfer of shares will be effected. In order to be eligible to attend and vote at the AGM, all share transfer documents accompanied by the relevant share certificates and other relevant documents, if any, must be lodged with Tricor Investor Services Limited, the Hong Kong branch share registrar of the Company, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on May 13, 2026.

To determine entitlement of the proposed final dividend (subject to the approval by the shareholders of the Company at the AGM), the register of members of the Company will be closed from May 28, 2026 to May 29, 2026, both dates inclusive, during which period no transfer of shares will be effected. In order to qualify for the proposed final dividend, all transfer documents accompanied by the relevant share certificates and other relevant documents, if any, must be lodged with Tricor Investor Services Limited, the Hong Kong branch share registrar of the Company, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on May 27, 2026.

5. All time and dates referred to in this notice refer to Hong Kong time and dates.

*As at the date of this notice, the executive directors of the Company are Mr. Zhang Yu, Mr. Zhang Hui and Ms. Han Zhimei; the non-executive director of the Company is Mr. Geng Jiaqi and the independent non-executive directors of the Company are Ms. Liang Jihong, Mr. Chan Peng Kuan and Mr. Li Xiaopei.*